Skip to content

Study · Non-randomized trial · n = 36 · 2026

8 results

Semaglutide improves markers of cardiovascular risk in people with HIV.

Lake JE, Kitch DW, Kantor A, Alonso C, Belaunzaran-Zamudio PF, Kulik GL, Hyatt AN, Fichtenbaum CJ, Brown TT, Landay A, Sattler F, Erlandson KM

AIDS (London, England)4 May 2026Cited by 1 (Europe PMC)

PMID42084141 (opens in a new tab)PMCIDPMC13573316 (opens in a new tab)DOI10.1097/qad.0000000000004538 (opens in a new tab)PepBankPUB-42084141
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In people with HIV and steatotic liver disease who lost weight on semaglutide, serum triglycerides, diglycerides and sphingomyelins fell.

    In plain wordsIn people with HIV and fatty liver disease who lost weight on semaglutide, some blood fats fell.

    Peptide
    Semaglutide
    Outcome
    DecreaseTriglycerides, diglycerides and sphingomyelins
    Study

    n = 36

    Analysis
    Exploratory
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    1 mg weeklyAs given in this study (human).

    Source sentences

    Summary
    semaglutide reduced triglycerides, diglycerides, and sphingomyelins
    2 context sentences
    Summary · context
    Secondary analysis of SLIM LIVER (ACTG A5371), an open-label, phase 2b, single-arm trial of 1 mg semaglutide weekly in adult people with HIV (PWH) and metabolic dysfunction-associated steatotic liver disease.
    Summary · context
    Participants ( n  = 36) experiencing clinical response (>5 lb weight loss) to semaglutide were included.
  2. 02HumanNon-randomized trialEfficacy outcome

    In people with HIV and steatotic liver disease who lost weight on semaglutide, some bile acids and phosphatidylcholines rose.

    In plain wordsIn people with HIV and fatty liver disease who lost weight on semaglutide, some bile acids and phosphatidylcholine fats rose.

    Peptide
    Semaglutide
    Outcome
    IncreaseBile acids and phosphatidylcholines
    Study

    n = 36

    Analysis
    Exploratory
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    1 mg weeklyAs given in this study (human).

    Source sentences

    Summary
    increased some bile acids and phosphatidylcholines.
    2 context sentences
    Summary · context
    Secondary analysis of SLIM LIVER (ACTG A5371), an open-label, phase 2b, single-arm trial of 1 mg semaglutide weekly in adult people with HIV (PWH) and metabolic dysfunction-associated steatotic liver disease.
    Summary · context
    Participants ( n  = 36) experiencing clinical response (>5 lb weight loss) to semaglutide were included.
  3. 03HumanNon-randomized trialEfficacy outcome

    In people with HIV and steatotic liver disease who lost weight on semaglutide, cardiovascular-disease-linked lipoprotein species decreased.

    In plain wordsIn people with HIV and fatty liver disease who lost weight on semaglutide, blood particles linked to heart disease decreased.

    Peptide
    Semaglutide
    Outcome
    DecreaseCVD-linked lipoprotein species
    Study

    n = 36

    Analysis
    Exploratory
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    1 mg weeklyAs given in this study (human).

    Source sentences

    Summary
    CVD-linked species decreased
    2 context sentences
    Summary · context
    Secondary analysis of SLIM LIVER (ACTG A5371), an open-label, phase 2b, single-arm trial of 1 mg semaglutide weekly in adult people with HIV (PWH) and metabolic dysfunction-associated steatotic liver disease.
    Summary · context
    Participants ( n  = 36) experiencing clinical response (>5 lb weight loss) to semaglutide were included.
  4. 04HumanNon-randomized trialEfficacy outcome

    In people with HIV and steatotic liver disease who lost weight on semaglutide, LDL particle size increased.

    In plain wordsIn people with HIV and fatty liver disease who lost weight on semaglutide, LDL particles grew larger.

    Peptide
    Semaglutide
    Outcome
    IncreaseLDL particle size
    Study

    n = 36

    Analysis
    Exploratory
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    1 mg weeklyAs given in this study (human).

    Source sentences

    Summary
    LDL particle size increased
    2 context sentences
    Summary · context
    Secondary analysis of SLIM LIVER (ACTG A5371), an open-label, phase 2b, single-arm trial of 1 mg semaglutide weekly in adult people with HIV (PWH) and metabolic dysfunction-associated steatotic liver disease.
    Summary · context
    Participants ( n  = 36) experiencing clinical response (>5 lb weight loss) to semaglutide were included.
  5. 05HumanNon-randomized trialEfficacy outcome

    In people with HIV and steatotic liver disease who lost weight on semaglutide, the number of large HDL particles decreased.

    In plain wordsIn people with HIV and fatty liver disease who lost weight on semaglutide, the number of large HDL particles decreased.

    Peptide
    Semaglutide
    Outcome
    DecreaseLarge HDL particle number
    Study

    n = 36

    Analysis
    Exploratory
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    1 mg weeklyAs given in this study (human).

    Source sentences

    Summary
    large HDL particle number decreased.
    2 context sentences
    Summary · context
    Secondary analysis of SLIM LIVER (ACTG A5371), an open-label, phase 2b, single-arm trial of 1 mg semaglutide weekly in adult people with HIV (PWH) and metabolic dysfunction-associated steatotic liver disease.
    Summary · context
    Participants ( n  = 36) experiencing clinical response (>5 lb weight loss) to semaglutide were included.
  6. 06HumanNon-randomized trialEfficacy outcome

    In people with HIV and steatotic liver disease on semaglutide, GlycA improved in 56% of participants with elevated baseline GlycA and normalized in 32%.

    In plain wordsIn people with HIV and fatty liver disease on semaglutide, an inflammation marker, GlycA, improved in many of those with high baseline levels.

    Peptide
    Semaglutide
    Outcome
    DecreaseGlycA in participants with elevated baseline GlycA
    Study

    n = 36

    Analysis
    Exploratory
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    1 mg weeklyAs given in this study (human).

    Measurements

    Participants with improved GlycA
    56%
    elevated baseline GlycA
    Participants with normalized GlycA
    32%
    elevated baseline GlycA

    Source sentences

    Summary
    56% with elevated Glyc A improved and 32% normalized; 41% with elevated Glyc B improved and 42% normalized.
    2 context sentences
    Summary · context
    Secondary analysis of SLIM LIVER (ACTG A5371), an open-label, phase 2b, single-arm trial of 1 mg semaglutide weekly in adult people with HIV (PWH) and metabolic dysfunction-associated steatotic liver disease.
    Summary · context
    Participants ( n  = 36) experiencing clinical response (>5 lb weight loss) to semaglutide were included.
  7. 07HumanNon-randomized trialEfficacy outcome

    In people with HIV and steatotic liver disease on semaglutide, GlycB improved in 41% of participants with elevated baseline GlycB and normalized in 42%.

    In plain wordsIn people with HIV and fatty liver disease on semaglutide, an inflammation marker, GlycB, improved in many of those with high baseline levels.

    Peptide
    Semaglutide
    Outcome
    DecreaseGlycB in participants with elevated baseline GlycB
    Study

    n = 36

    Analysis
    Exploratory
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    1 mg weeklyAs given in this study (human).

    Measurements

    Participants with improved GlycB
    41%
    elevated baseline GlycB
    Participants with normalized GlycB
    42%
    elevated baseline GlycB

    Source sentences

    Summary
    56% with elevated Glyc A improved and 32% normalized; 41% with elevated Glyc B improved and 42% normalized.
    2 context sentences
    Summary · context
    Secondary analysis of SLIM LIVER (ACTG A5371), an open-label, phase 2b, single-arm trial of 1 mg semaglutide weekly in adult people with HIV (PWH) and metabolic dysfunction-associated steatotic liver disease.
    Summary · context
    Participants ( n  = 36) experiencing clinical response (>5 lb weight loss) to semaglutide were included.
  8. 08HumanNon-randomized trialMechanism

    In people with HIV and steatotic liver disease on semaglutide, lipoprotein and glycoprotein concentrations generally did not correlate with baseline weight, liver fat or insulin resistance, or with their changes.

    In plain wordsIn people with HIV and fatty liver disease on semaglutide, blood lipoprotein levels mostly did not track weight, liver fat or insulin resistance.

    Peptide
    Semaglutide
    Outcome
    No significant changeCorrelation of lipoprotein/glycoprotein concentrations with baseline weight, liver fat and insulin resistance
    Study

    n = 36

    Analysis
    Exploratory
    Outcome group
    Inflammation markers · Metabolic and weight
    Studied dose
    1 mg weeklyAs given in this study (human).

    Source sentences

    Summary
    Lipoprotein/glycoprotein concentrations generally did not correlate with baseline weight, liver fat, or insulin resistance or their magnitude of change.
    2 context sentences
    Summary · context
    Secondary analysis of SLIM LIVER (ACTG A5371), an open-label, phase 2b, single-arm trial of 1 mg semaglutide weekly in adult people with HIV (PWH) and metabolic dysfunction-associated steatotic liver disease.
    Summary · context
    Participants ( n  = 36) experiencing clinical response (>5 lb weight loss) to semaglutide were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.